Drugs / GSK2647544
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01978327 | Nov 2013 → Mar 2014 | Alzheimer disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01924858 | Aug 2013 → Mar 2014 | Alzheimer disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01702467 | Oct 2012 → May 2013 | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2647544 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01924858 ↗ |
| Action | Inhibit | “selective inhibitor of Lp PLA2” NCT01978327 ↗ |
| Modality | Small molecule | — CHEMBL3634561 ↗ |
| Route | Oral | “Single, Oral Escalating Doses of GSK2647544” NCT01702467 ↗ |